Scrip
Novo Nordisk's diabetes drug liraglutide stumbles on thyroid cancer concerns
03 April 2009
Sue Sutter
Novo Nordisk's GLP-1 analogue Victoza (liraglutide) injection does not present an excessive cardiovascular risk, but questions about thyroid carcinogenicity may preclude approval of the agent for type 2 diabetes, the US
FDA's outside experts have said.
The endocrinologic and metabolic drugs advisory...
Please Login to read the full article.
03 April 2009
Sue Sutter
The endocrinologic and metabolic drugs advisory...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Once-weekly Byetta could get similar thyroid cancer warning as Victoza
- US panel backs Theratechnologies' Egrifta for HIV lipodystrophy
- NAS in 2009: Industry R&D productivity sees slump on previous year
- Antidiabetic GLP-1s only linked to thyroid cancer in rodents, study suggests
COMMENT
Other Informa Comment
EVENTS
01 January 1970
London, UK
01 January 1970
San Diego, US
01 January 1970
Providence, Rhode Island, and San Francisco, California
JOB OF THE WEEK
Promote your vacancy here
